TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39468623
Drug: Functional hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional hip abductor strength training combined with traditional physical therapy
Study: 39468632
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment followed by cast immobilization
Study: 39468643
Drug: Green coffee
Normalized name: Green coffee bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green coffee (GC) capsules (800 mg) daily for 6 months
Study: 39468701
Drug: Tucidinostat plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucidinostat plus pediatric-inspired chemotherapy
Study: 39469294
Drug: Virtually delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtually delivered mind-body program integrating tai chi, qigong, and meditation (VDTQM), 12-week program, live online 60-minute classes twice weekly.
Study: 39469536
Drug: CVN424 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVN424 50 mg
Study: 39469536
Drug: CVN424 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVN424 150 mg
Study: 39469537
Drug: Dietary inorganic
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary inorganic nitrate (70 mL of nitrate-containing beetroot juice) for 6 months
Study: 39469641
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of vemurafenib (vem), cobimetinib (cobi), and atezolizumab (atezo)
Study: 39469838
Drug: Dato-DXd +
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dato-DXd + pembrolizumab + platinum-based chemotherapy
Study: 39469838
Drug: pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab + pemetrexed + platinum chemotherapy
Study: 39470284
Drug: Point-of-care nucleic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care nucleic acid device using caregiver/patient self-collected buccal swabs
Study: 39470554
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) + medical treatment + stabilization splint
Study: 39470554
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical treatment + stabilization splint)
Study: 39470788
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy for adolescents (DBT-A)
Study: 39470875
Drug: Non-ablative diode
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative diode laser therapy
Study: 39471424
Drug: Selpercatinib 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selpercatinib 20 mg QD or 20-240 mg BID in phase I; 160 mg BID in phase II.
Study: 39471820
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic preconditioning (RIC) twice daily for 2-4 days before carotid artery stenting (CAS) as an adjunct to standard medical therapy
Study: 39472058
Drug: Hydrocortisone replacement
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone replacement (20 mg/day for 3 months, then 10 mg/day for 3 months)
Study: 39472058
Drug: Prednisone tapering
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tapering (1 mg/day every month until complete discontinuation)
Study: 39472058
Drug: Prednisone tapering
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tapering
Study: 39472354
Drug: uPAR-PET tracer
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: uPAR-PET tracer administration (approximately 200 MBq, range: 83-222 MBq)
Study: 39472409
Drug: Heated Tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated Tobacco Products (HTPs) inhalation
Study: 39472511
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of autologous platelet-rich plasma (PRP) 0.8-1 ml 48 hours before blastocyst ET in fresh and frozen cycles
Study: 39472511
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of autologous platelet-rich plasma (PRP)
Study: 39472511
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PRP infusion)
Study: 39472768
Drug: PRX004 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX004 (0.1, 0.3, 1, 3, 10 or 30 mg/kg), administered intravenously every 28 days for 3 months
Study: 39472768
Drug: PRX004 (≥3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX004 (≥3 mg/kg for ≥9 months)
Study: 39472831
Drug: Intrauterine misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine misoprostol (400 mg) + oxytocin
Study: 39472831
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 mg) + oxytocin
Study: 39472975
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (MCI) including health coaching, physician training, medication subsidy, and case review meetings
Study: 39473003
Drug: 0.2% hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% hyaluronic acid gel-impregnated dental floss
Study: 39473014
Drug: Computed precision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed precision doses of tDCS
Study: 39473017
Drug: High-risk patients
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk patients (APACHE II score ≥ 15, invasive pulmonary aspergillosis, therapeutic dose of anticoagulants, extracorporeal membrane oxygenation, continuous renal replacement therapy)
Study: 39473059
Drug: Neoadjuvant radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant radiation therapy and docetaxel (45 Gy radiotherapy in 25 fractions over 5 weeks, weekly dose-escalated docetaxel up to 30 mg/m²)
Study: 39473059
Drug: Neoadjuvant radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant radiation therapy and docetaxel
Study: 39473076
Drug: Crizanlizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizanlizumab (5 mg/kg)
Study: 39473704
Drug: Collagen paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen paste injection
Study: 39474720
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg/day
Study: 39475112
Drug: Sofosbuvir/velpatasvir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/velpatasvir treatment
Study: 39475399
Drug: Transcatheter tricuspid-valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter tricuspid-valve replacement and medical therapy
Study: 39475418
Drug: palbociclib +
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib + endocrine therapy (ET) in first-line (1L) setting
Study: 39475418
Drug: palbociclib +
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib + endocrine therapy (ET) in second-line or later (≥2L) setting
Study: 39475591
Drug: Onvansertib in
Normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onvansertib in combination with FOLFIRI + bevacizumab
Study: 39475817
Drug: Dapagliflozin, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin, dosage and duration not available
Study: 39475960
Drug: 6-, 11-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-, 11-, or 22-mg/day upadacitinib for 24 weeks
Study: 39475960
Drug: 6-, 11-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-, 11-, or 22-mg/day upadacitinib
Study: 39476073
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) targeting the prefrontal cortex, 5 days a week for 8 weeks followed by twice-a-year 5-day boosters and daily at-home CR.
Study: 39476101
Drug: Thrombopoietin receptor
Normalized name: Thrombopoietin receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombopoietin receptor agonists
Study: 39476124
Drug: Forimtamig (GPRC5D-targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forimtamig (GPRC5D-targeting T-cell bispecific antibody)
Study: 39476124
Drug: Forimtamig in
Normalized name: Forimtamig
DrugBank: Forimtamig (DB19015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forimtamig in combination with standard-of-care agents (anti-CD38 antibodies, immunomodulatory drugs, proteasome inhibitors)
Study: 39476124
Drug: Forimtamig in
Normalized name: Forimtamig
DrugBank: Forimtamig (DB19015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forimtamig in combination with novel therapeutic agents (BCMA-TCB and CELMoDs)
Study: 39476739
Drug: Probiotic toothpaste
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic toothpaste containing Lactobacillus paracasei, used twice a day for four weeks.
Study: 39476739
Drug: Regular toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular toothpaste (Colgate), used twice a day for four weeks.
Study: 39476808
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling program for mothers based on UNICEF dietary guidelines, followed by monthly phone calls
Study: 39477275
Drug: Iodised salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodised salt fortified with 30 ppm folic acid to provide ~200 µg folic acid/day
Study: 39477275
Drug: Iodised salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodised salt fortified with 90 ppm folic acid to provide ~600 µg folic acid/day
Study: 39477631
Drug: Standard-of-care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SoC) therapy withdrawal
Study: 39477631
Drug: Standard-of-care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SoC) therapy (not withdrawn)
Study: 39478521
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine infusion (5 μg/kg/min) for 24 hours after PCI
Study: 39478532
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg twice daily for 12 weeks, then open-label nintedanib for 12 weeks
Study: 39478814
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of home-based exercise and pulsed electromagnetic field (PEMF) therapy
Study: 39479862
Drug: Conventional second-line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional second-line chemotherapy
Study: 39480040
Drug: Poly l-lactic
Normalized name: L-Lactic acid
DrugBank: L-Lactic acid (DB14475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly l-lactic acid (PLLA-SCA)
Study: 39480379
Drug: Control second-generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control second-generation drug-eluting stent (DES)
Study: 39480380
Drug: TTVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT)
Study: 39480422
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinician peer comparison and patient informational mail
Study: 39480424
Drug: Low-magnitude mechanical
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-magnitude mechanical signals (LMMS) (0.3 g at 32-37 Hz) for 10 minutes daily for 6 months
Study: 39480424
Drug: Sham (placebo)
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (placebo) signals for 10 minutes daily for 6 months
Study: 39480453
Drug: Veliparib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (40 mg orally, twice daily, days 1-7) combined with temozolomide (150-200 mg/m2 orally, days 1-5) for 6 cycles
Study: 39480453
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with temozolomide (150-200 mg/m2 orally, days 1-5) for 6 cycles
Study: 39480530
Drug: FOLFOXIRI every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI every 2 weeks with routine G-CSF prophylaxis
Study: 39480764
Drug: Tegoprubart (anti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprubart (anti CD40L antibody) administered intravenously, 6 infusions every 2 weeks at doses of 1 mg/kg, 2 mg/kg, 4 mg/kg, and 8 mg/kg
Study: 39481054
Drug: Enfortumab Vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab Vedotin (EV) 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle
Study: 39481328
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula at 30 L/min (HFNC-30)
Study: 39481328
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula at 50 L/min (HFNC-50)
Study: 39481395
Drug: Camizestrant 75
Normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camizestrant 75 mg
Study: 39481395
Drug: Camizestrant 150
Normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camizestrant 150 mg
Study: 39481425
Drug: DynamX bioadaptor
Normalized name: LIDOCAINE 10 mg in 0.08 mL TOPICAL SPRAY [DYNAMO DELAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DynamX bioadaptor (Elixir Medical)
Study: 39481541
Drug: Mungbean dal
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [KG-Dal HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mungbean dal with fresh guava (3.2 mg iron; ∼170 mg vitamin C; molar ratio ∼18:1)
Study: 39481541
Drug: Mungbean dal
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [KG-Dal HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mungbean dal only (3.0 mg iron; vitamin C:iron molar ratio ∼0.5:1)
Study: 39481880
Drug: neoadjuvant platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant platinum-based chemotherapy followed by surgery
Study: 39482336
Drug: Inhaled Recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Recombinant COVID-19 Vaccine (Ad5-nCoV-IH)
Study: 39482336
Drug: Intramuscular tozinameran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tozinameran (BNT-IM)
Study: 39482484
Drug: Low-dose interleukin
Normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin 2 (Ld-IL2) therapy along with standard treatment for 12 weeks
Study: 39482712
Drug: Citrus peel
Normalized name: CITRUS AURANTIUM PEEL OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus peel extract (400 mg containing 3.0 mg of naringenin and 0.1 mg of auraptene)
Study: 39482930
Drug: Toripalimab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (240 mg) + bevacizumab (7.5 mg/kg) + platinum-based chemotherapy (once every three weeks for six cycles, followed by maintenance therapy for 12 months)
Study: 39483442
Drug: Group Metacognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Metacognitive Therapy (MCT) added to usual CR
Study: 39483517
Drug: Deferred local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred local treatment of the primary tumour (experimental arm) consisting of (partial) cytoreductive nephrectomy, any form of ablative local therapy, or magnetic resonance imaging guided ablative stereotactic radiotherapy, performed within 6 months and 1.5 years after the start of systemic treatment.
Study: 39483518
Drug: Analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analysis of patient subgroup response to bacillus Calmette-Guérin treatment.
Study: 39484118
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use at baseline
Study: 39484240
Drug: aTIV (adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: aTIV (adjuvanted trivalent inactivated flu vaccine)
Study: 39484240
Drug: HD-IIV3 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-IIV3 (high-dose flu vaccine)
Study: 39485256
Drug: Personalized neoantigen-encoding
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized neoantigen-encoding mRNA vaccines
Study: 39485256
Drug: Individualized vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized vaccines plus pembrolizumab
Study: 39485259
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of the intervention (specific intervention not mentioned)
Study: 39485351
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion strategy (Hb <10 g/dL)
Study: 39485351
Drug: Restrictive RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive RBC transfusion strategy (Hb <7-8 g/dL)
Study: 39486046
Drug: Pegcetacoplan 270
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegcetacoplan 270 mg/day
Study: 39486046
Drug: Pegcetacoplan 360
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegcetacoplan 360 mg/day
Study: 39486089
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ibuzatrelvir
Study: 39486089
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ibuzatrelvir
Study: 39486089
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuzatrelvir
Study: 39486209
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment supplemented with PNE
Study: 39486411
Drug: Neoadjuvant TLR9
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab
Study: 39486424
Drug: Chemotherapy (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (carboplatin plus pemetrexed)
Study: 39486432
Drug: Valemetostat 150
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valemetostat 150 mg per day
Study: 39486432
Drug: Valemetostat 200
Normalized name: tazemetostat 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valemetostat 200 mg per day
Study: 39486432
Drug: Valemetostat 250
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valemetostat 250 mg per day
Study: 39486432
Drug: Valemetostat 300
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valemetostat 300 mg per day
Study: 39486433
Drug: Valemetostat at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valemetostat at 200 mg per day in continuous 28-day cycles until disease progression or unacceptable toxicity
Study: 39486645
Drug: MDT (definitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT (definitive local treatment to all sites of disease, plus SOC systemic therapy)
Study: 39486645
Drug: SOC systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC systemic therapy-only
Study: 39486886
Drug: Selective HDAC
Normalized name: Hdac-in-4
DrugBank: CXD101 (DB16182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective HDAC inhibition in combination with immunotherapy (specifics on dosage and duration not available)
Study: 39486892
Drug: Automated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated oxygen administration (AOA) via the O2matic device
Study: 39486892
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (manual oxygen administration)
Study: 39487326
Drug: Adapalene 0.1%-clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1%-clindamycin 1% combination gel
Study: 39487326
Drug: Clindamycin 1%
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% monotherapy
Study: 39487337
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cilostazol daily for 7 days
Study: 39487337
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rosuvastatin daily for 7 days
Study: 39487337
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 200 mg cilostazol and 20 mg rosuvastatin daily for 7 days
Study: 39487373
Drug: Adavosertib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (200 mg qd or 175 mg bid) plus Olaparib (200 mg bid)
Study: 39487711
Drug: Nab-sirolimus (ABI-009)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-sirolimus (ABI-009) administered IV on days 1 and 8 of cycle 1, in combination with temozolomide (125 mg/m2) and irinotecan.
Study: 39487711
Drug: Nab-sirolimus (ABI-009)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-sirolimus (ABI-009) at maximum tolerated dose (MTD) of 15 mg/m2.
Study: 39488138
Drug: Vaginal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal laser treatment (3-6 applications)